SCHEMBL16234571

SCHEMBL16234571

CCC(=O)Nc1cc(C(=O)NCc2cnc(OCC(F)(F)F)c(C(F)(F)F)c2)cc(C)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 1/20 0.44
EPHX2 P34913 2/20 0.36
PTK2 Q05397 2/20 0.35
KDM4E B2RXH2 1/20 0.35
GLA P06280 1/20 0.35
PTGES O14684 2/20 0.34
RIPK1 Q13546 3/20 0.34
ADORA3 P0DMS8 2/20 0.34
ALDH1A1 P00352 1/20 0.34
TP53 P04637 1/20 0.34
ADORA1 P30542 1/20 0.34
MAPT P10636 1/20 0.34
PPARG P37231 1/20 0.34
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
KCNH2 Q12809 1/20 0.33
SCN5A Q14524 1/20 0.33
SCN2A Q99250 1/20 0.33
SCN10A Q9Y5Y9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2715783 0.92 SCN9A (0.44) SCN9AEPHX2PTGESRIPK1ADORA3
SCHEMBL2717853 0.91 SCN9A (0.47) SCN9AEPHX2KDM4EPTGESRIPK1
SCHEMBL2714447 0.91 SCN9A (0.44) SCN9APTGESRIPK1ADORA3ALDH1A1
SCHEMBL2717497 0.91 SCN9A (0.45) SCN9AEPHX2PTK2RIPK1MAPT
SCHEMBL2716783 0.89 SCN9A (0.42) SCN9AEPHX2RIPK1ADORA3ADORA1
SCHEMBL2716980 0.89 SCN9A (0.42) SCN9AKDM4EPTGESRIPK1ADORA3
SCHEMBL2716580 0.86 GSK3B (0.46) SCN9AEPHX2MAPTSMN1; SMN2KCNH2
SCHEMBL2717677 0.84 PTGES (0.45) SCN9AEPHX2PTGES
SCHEMBL2716797 0.83 SCN9A (0.48) SCN9AEPHX2RIPK1MAPTKCNH2
SCHEMBL15350146 0.83 SCN9A (0.40) SCN9AEPHX2KDM4EPTGESRIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140336377-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2014-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336377-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS SCN2B, SCN1B, SCN2A SCN9A 31/4885EPHX2 2460/4885PTK2 4616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.